Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

• DOI: 10.1136/jitc-2020-001511
• Publication Date: 2020-12-30T18:11:50Z
• Authors: Marcela V Maus; Sara Alexander; Michael R Bishop; Jennifer N Brudno; Colleen Callahan; Marco L Davila; Claudia Diamonte; Jorg Dietrich; Julie C Fitzgerald; Matthew J Frigault; Terry J Fry; Jennifer L Holter...; Krishna V Komanduri; Daniel W Lee; Frederick L Locke; Shannon L Maude; Philip L McCarthy; Elena Mead; Sattva S Neelapu; Tomas G Neilan; Bianca D Santomasso; Elizabeth J Shpall; David T Teachey; Cameron J Turtle; Tom Whitehead; Stephan A Grupp
• Keywords: Cytokine Release Syndrome; Guideline

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric adult a number disease states, as 'living drugs,' their toxicity profiles, including cytokine release syndrome (CRS) immune cell-associated neurotoxicity (ICANS), differ markedly from conventional cancer therapeutics. At the time article preparation, US Food Drug Administration (FDA) has approved tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, all which are IEC based on genetically modified T cells engineered to express chimeric antigen receptors (CARs), additional products expected reach marketing authorization soon enter clinical development due course. As therapies, especially CAR more widespread use, there is need clear, cohesive recommendations management, motivating Society Immunotherapy Cancer (SITC) convene an expert panel develop practice guideline. The discussed recognition management common toxicities context treatment, baseline laboratory parameters monitoring, timing onset, pharmacological interventions, ultimately forming evidence- consensus-based assist medical professionals decision-making improve patients.